TraumaPhase 4NCT01692769
Trial Of Normal Saline Versus Ringer's Lactate In Paediatric Trauma Patients
A Phase 4 study testing Normal Saline and Ringer's Lactate in people with Trauma, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
Trial summary
Background: Trauma is a major cause of death in children and teenagers. When young patients have suffered major traumatic injuries, they require intravenous (iv) fluids to keep their blood vessels full and ensure blood flow to vital organs. Read more about this study
- Who is it for?
- Ages 1 year to 17 years
- Conditions the study is for
- Trauma
- What is being tested?
- Normal Saline and Ringer's Lactate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteCanada
- Study dates
- May 2013to Dec 2014
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Pediatric trauma patients with Injury Severity Score greater than 12
- Age 1-17 years
- Trauma within 8 hours
Who cannot join
- Injury Severity Score less than 12
- Pre-existing renal disease
- On medication that affects serum sodium (i.e diuretic therapy)
- Blood transfusion within first 24 hours
- Operation within first 24 hours
- Oral intake of fluid or solids in first 24 hours
Trial locations and contacts
1 site in 1 country.
Canada1 site
Children's Hospital, London Health Sciences Centre
London, Ontario, N6A5W9
About this study
Official title: Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate
Background: Trauma is a major cause of death in children and teenagers. When young patients have suffered major traumatic injuries, they require intravenous (iv) fluids to keep their blood vessels full and ensure blood flow to vital organs. Current fluid guidelines by International Trauma Committees recommend either Normal Saline (NS) or Ringer's Lactate (RL) as the fluid of choice for these patients. Although these solutions share some similarities in their composition, there are also some significant differences in sodium, chloride and lactate concentrations. Despite these differences in fluid composition, there has never been a study comparing these two fluids in paediatric trauma patients to determine which is optimal. In this study, the investigators aim to determine the optimal fluid choice for trauma resuscitation of young patients.
Hypothesis: The investigators hypothesize that severely injured paediatric trauma patients resuscitated with NS will have optimal blood sodium levels compared to patients resuscitated with RL.
Read more
Methods: The investigators will study 50 paediatric trauma patients that will be randomized so that half will randomly receive NS and half will receive RL as their only iv fluid for 24 hours. After 24 hours, the investigators will compare in blood the sodium level, the amount of acid, and the concentrations of inflammation molecules in relation to those whom received NS versus RL.
Expected Results and Significance: Maintaining optimal levels of these biochemical markers is imperative in reducing morbidity and mortality in severely injured paediatric patients. If significant differences are present, the investigators will be able to determine which fluid is preferred and expect these data to complement current trauma resuscitation guidelines.
Read the detailed description
Background:
Trauma is the major killer of children and adolescents. The care of paediatric trauma patients is guided by the Advanced Trauma Life Support (ATLS) guidelines. Fluid resuscitation is a critical aspect of trauma resuscitation to avoid hypoperfusion and metabolic acidosis, and to maintain adequate oxygen delivery to tissues. ATLS recommends the use of either intravenous Normal Saline (NS) or Ringer's Lactate (RL) in trauma fluid resuscitation. There are currently no recommendations or any studies to suggest which of these two fluids are more appropriate for pediatric trauma patients and their ionic compositions do differ. As such, both solutions have potential benefits and potential complications.
There are three primary issues that relate to choice of solution.
- Sodium concentration and risk of iatrogenic hyponatremia: NS has higher sodium content relative to RL (154 vs. 130 mmol/L, respectively; normal blood levels are 135-145 mmol/L). Maintenance of a normal or slightly elevated sodium level in paediatric trauma patients is often imperative, given that the vast majority of these patients have significant traumatic brain injury. Hyponatremia can worsen cerebral edema and increase intracranial pressure. In a previous study conducted by us at Children's Hospital, LHSC we reported that paediatric trauma patients in our centre received NS. Despite NS used as the resuscitation fluid, pediatric trauma patients all showed a trend towards low-normal levels of sodium in their blood. Given the lower content of sodium in RL, we question whether NS is superior for maintenance of blood sodium.
- Chloride concentration and risk of iatrogenic hyperchloremic metabolic acidosis: NS contains significantly more chloride than RL to maintain electro-neutrality (154 vs. 109 mmol, respectively; normal blood levels are 98-108 mmol/L). In contrast, the RL solution replaces 28 mmol/L of chloride with equimolar lactate. As the elevated chloride content in NS is postulated to instigate the undesired consequences of driving blood bicarbonate lower and producing a hyperchloremic metabolic acidosis,6, 7 we question whether NS is inferior to RL for maintenance of blood pH.
- Exacerbation of trauma-induced inflammation: Trauma results in a systemic inflammatory response (Fraser Lab, unpublished results). Exacerbation of the inflammatory state with non-optimal resuscitation practices might worsen overall outcome. Published data on non-trauma patients suggests that NS administration is pro-inflammatory relative to RL,9 but this possibility has not been studied in paediatric patients, or in any trauma patients. The inflammatory cascade can be assessed in blood by measuring the levels of global inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)] and specific pro-inflammatory mediators elevated by multisystem trauma [interleukin-6 (IL-6), interleukin-8 (IL-8), granulocyte colony stimulating factor (G-CSF) and monocyte chemotactic protein-1 (MCP-1)]. Given the higher inflammatory potential that has been associated with NS, we question whether NS is inferior to RL for minimizing inflammatory cascades.
Hypothesis:
We hypothesize that severely injured paediatric trauma patients resuscitated with NS will have optimal blood sodium levels compared to patients resuscitated with RL, but at the expense of hyperchloremic metabolic acidosis and exaggerated inflammation.
Methodology:
This study will be a prospective, single-blinded, RCT of severely injured paediatric trauma patients admitted to the Children's Hospital, London Health Sciences Centre. While the clinical staff treating the patient will be aware of treatment group, the patient, as well as the laboratory technicians determining the serum changes will be blinded to the fluid administered.
Randomization:
Patients will be immediately randomized to either receive NS or RL as their resuscitation and maintenance fluid for the first 24 hours. Randomization, via selection of sealed envelope based on a computer-generated list, will be done by the trauma resuscitation room intravenous access nurse without delay on arrival. Intravenous access and solution administration occurs as a priority within minutes of arrival to the trauma room.
Clinical Data and Blood Analyses:
All patients included in this study will be entered into the LHSC Trauma Database, comprised of over 400 data elements, by a single, trained Trauma Data Analyst. The database regularly undergoes quality monitoring to ensure the data is complete and is of highest quality. Descriptive analyses and epidemiologic profiles on demographic, clinical and injury data will be undertaken, as we have published previously. A baseline trauma blood panel will be drawn upon presentation to our resuscitation room (Time "0"), and then repeated at 24 hours. Blood measurements for analyses will include serum sodium, chloride, bicarbonate, base excess, osmolality, blood gas, ESR and CRP. An extra blood vial will be taken and stored for batch analyses of pro-inflammatory cytokines by multiplex assay (IL- 6, IL-8, G-CSF and MCP-1). Other interventions will be carried out as per standard of care at the discretion of the Trauma most responsible physician. Any medications or any additional fluids the patients receive will be recorded. The total amount of intravenous fluid received in the first 24 hours will be measured for all patients.
Data Analysis:
Descriptive analyses and epidemiologic profiles on demographic, clinical and injury data will be undertaken, as we have published previously.
Treatment groups will be compared using Mann Whitney U test for the outcome measures at 24 hours, as they are continuous. This will include the primary outcome variable (serum sodium) and the secondary outcome variables (serum chloride, bicarbonate, pH and inflammatory markers: ESR, C-RP, IL-6, Il-8, G-CSF, MCP-1).
- Conditions
- Trauma
- Being tested
- Normal Saline, Ringer's Lactate
- Keywords
- Trauma, Pediatric, Intravenous Fluid, Normal Saline, Ringer's Lactate
- Medical subject headings
- Wounds and Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Normal SalineDrug
Also called 0.9% Normal Saline
Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Ringer's LactateDrug
Also called Lactated Ringers
Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
| Study group | Role | What they receive |
|---|---|---|
| Normal Saline | Active comparator | Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital. Receives: Drug: Normal Saline |
| Ringer's Lactate | Active comparator | Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital. Receives: Drug: Ringer's Lactate |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in serum sodium change over 24 hours between patients receiving NS versus RL
Measured: 24 hours
Secondary outcomes (9)
The difference in serum pH
Measured: 24 hours
The difference serum chloride
Measured: 24 hours
The differences in serum bicarbonate
Measured: 24 hours
The differences in serum inflammatory biomarker change: Erythrocyte Sedimentation Rate (ESR)
Measured: 24 hours
The differences in serum inflammatory biomarker change: C-Reactive Protein
Measured: 24 hours
The differences in serum inflammatory biomarker change: InterLeukin-6
Measured: 24 hours
The differences in serum inflammatory biomarker change InterLeukin-8
Measured: 24 hours
The differences in serum inflammatory biomarker change: G-CSF
Measured: 24 hours
The differences in serum inflammatory biomarker change: MCP-1
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2012 (estimated)
- Study startMay 2013
- Primary completionAug 2014
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TraumaStudies of the same condition, open and under way.
- More trials run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gurinder S Sangha, MD, Principal investigator, London Health Sciences Centre, University of Western OntarioDouglas D Fraser, MD, PhD, Principal investigator, London Health Sciences Centre, University of Western Ontario
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01692769
- Sponsor's protocol ID
- 102632
- Status last verified
- Nov 2018
- First submitted
- 19 Sep 2012
- Last updated
- 6 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate
- ClinicalTrials.gov ID
- NCT01692769
- Acronym / sponsor ID
- 102632
- Conditions
- Trauma
- Keywords
- Trauma, Pediatric, Intravenous Fluid, Normal Saline, Ringer's Lactate
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Study start
- May 2013 (actual)
- Primary completion
- Aug 2014 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 25 Sep 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Trauma is a major cause of death in children and teenagers. When young patients have suffered major traumatic injuries, they require intravenous (iv) fluids to keep their blood vessels full and ensure blood flow to vital organs. Current fluid guidelines by International Trauma Committees recommend either Normal Saline (NS) or Ringer's Lactate (RL) as the fluid of choice for these patients. Although these solutions share some similarities in their composition, there are also some significant differences in sodium, chloride and lactate concentrations. Despite these differences in fluid composition, there has never been a study comparing these two fluids in paediatric trauma patients to determine which is optimal. In this study, the investigators aim to determine the optimal fluid choice for trauma resuscitation of young patients.
Hypothesis: The investigators hypothesize that severely injured paediatric trauma patients resuscitated with NS will have optimal blood sodium levels compared to patients resuscitated with RL.
Methods: The investigators will study 50 paediatric trauma patients that will be randomized so that half will randomly receive NS and half will receive RL as their only iv fluid for 24 hours. After 24 hours, the investigators will compare in blood the sodium level, the amount of acid, and the concentrations of inflammation molecules in relation to those whom received NS versus RL.
Expected Results and Significance: Maintaining optimal levels of these biochemical markers is imperative in reducing morbidity and mortality in severely injured paediatric patients. If significant differences are present, the investigators will be able to determine which fluid is preferred and expect these data to complement current trauma resuscitation guidelines.
Detailed description
Background:
Trauma is the major killer of children and adolescents. The care of paediatric trauma patients is guided by the Advanced Trauma Life Support (ATLS) guidelines. Fluid resuscitation is a critical aspect of trauma resuscitation to avoid hypoperfusion and metabolic acidosis, and to maintain adequate oxygen delivery to tissues. ATLS recommends the use of either intravenous Normal Saline (NS) or Ringer's Lactate (RL) in trauma fluid resuscitation. There are currently no recommendations or any studies to suggest which of these two fluids are more appropriate for pediatric trauma patients and their ionic compositions do differ. As such, both solutions have potential benefits and potential complications.
There are three primary issues that relate to choice of solution.
- Sodium concentration and risk of iatrogenic hyponatremia: NS has higher sodium content relative to RL (154 vs. 130 mmol/L, respectively; normal blood levels are 135-145 mmol/L). Maintenance of a normal or slightly elevated sodium level in paediatric trauma patients is often imperative, given that the vast majority of these patients have significant traumatic brain injury. Hyponatremia can worsen cerebral edema and increase intracranial pressure. In a previous study conducted by us at Children's Hospital, LHSC we reported that paediatric trauma patients in our centre received NS. Despite NS used as the resuscitation fluid, pediatric trauma patients all showed a trend towards low-normal levels of sodium in their blood. Given the lower content of sodium in RL, we question whether NS is superior for maintenance of blood sodium.
- Chloride concentration and risk of iatrogenic hyperchloremic metabolic acidosis: NS contains significantly more chloride than RL to maintain electro-neutrality (154 vs. 109 mmol, respectively; normal blood levels are 98-108 mmol/L). In contrast, the RL solution replaces 28 mmol/L of chloride with equimolar lactate. As the elevated chloride content in NS is postulated to instigate the undesired consequences of driving blood bicarbonate lower and producing a hyperchloremic metabolic acidosis,6, 7 we question whether NS is inferior to RL for maintenance of blood pH.
- Exacerbation of trauma-induced inflammation: Trauma results in a systemic inflammatory response (Fraser Lab, unpublished results). Exacerbation of the inflammatory state with non-optimal resuscitation practices might worsen overall outcome. Published data on non-trauma patients suggests that NS administration is pro-inflammatory relative to RL,9 but this possibility has not been studied in paediatric patients, or in any trauma patients. The inflammatory cascade can be assessed in blood by measuring the levels of global inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)] and specific pro-inflammatory mediators elevated by multisystem trauma [interleukin-6 (IL-6), interleukin-8 (IL-8), granulocyte colony stimulating factor (G-CSF) and monocyte chemotactic protein-1 (MCP-1)]. Given the higher inflammatory potential that has been associated with NS, we question whether NS is inferior to RL for minimizing inflammatory cascades.
Hypothesis:
We hypothesize that severely injured paediatric trauma patients resuscitated with NS will have optimal blood sodium levels compared to patients resuscitated with RL, but at the expense of hyperchloremic metabolic acidosis and exaggerated inflammation.
Methodology:
This study will be a prospective, single-blinded, RCT of severely injured paediatric trauma patients admitted to the Children's Hospital, London Health Sciences Centre. While the clinical staff treating the patient will be aware of treatment group, the patient, as well as the laboratory technicians determining the serum changes will be blinded to the fluid administered.
Randomization:
Patients will be immediately randomized to either receive NS or RL as their resuscitation and maintenance fluid for the first 24 hours. Randomization, via selection of sealed envelope based on a computer-generated list, will be done by the trauma resuscitation room intravenous access nurse without delay on arrival. Intravenous access and solution administration occurs as a priority within minutes of arrival to the trauma room.
Clinical Data and Blood Analyses:
All patients included in this study will be entered into the LHSC Trauma Database, comprised of over 400 data elements, by a single, trained Trauma Data Analyst. The database regularly undergoes quality monitoring to ensure the data is complete and is of highest quality. Descriptive analyses and epidemiologic profiles on demographic, clinical and injury data will be undertaken, as we have published previously. A baseline trauma blood panel will be drawn upon presentation to our resuscitation room (Time "0"), and then repeated at 24 hours. Blood measurements for analyses will include serum sodium, chloride, bicarbonate, base excess, osmolality, blood gas, ESR and CRP. An extra blood vial will be taken and stored for batch analyses of pro-inflammatory cytokines by multiplex assay (IL- 6, IL-8, G-CSF and MCP-1). Other interventions will be carried out as per standard of care at the discretion of the Trauma most responsible physician. Any medications or any additional fluids the patients receive will be recorded. The total amount of intravenous fluid received in the first 24 hours will be measured for all patients.
Data Analysis:
Descriptive analyses and epidemiologic profiles on demographic, clinical and injury data will be undertaken, as we have published previously.
Treatment groups will be compared using Mann Whitney U test for the outcome measures at 24 hours, as they are continuous. This will include the primary outcome variable (serum sodium) and the secondary outcome variables (serum chloride, bicarbonate, pH and inflammatory markers: ESR, C-RP, IL-6, Il-8, G-CSF, MCP-1).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal Saline | Active comparator | Drug: Normal SalinePatients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital. |
| Ringer's Lactate | Active comparator | Drug: Ringer's LactatePatients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital. |
Who may qualify
- Ages
- 1 year to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Pediatric trauma patients with Injury Severity Score greater than 12
- Age 1-17 years
- Trauma within 8 hours
Key exclusion criteria (6 listed)
- Injury Severity Score less than 12
- Pre-existing renal disease
- On medication that affects serum sodium (i.e diuretic therapy)
- Blood transfusion within first 24 hours
- Operation within first 24 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Normal SalineAlso: 0.9% Normal SalinePatients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital. | Drug | Normal Saline |
| Ringer's LactateAlso: Lactated RingersPatients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital. | Drug | Ringer's Lactate |
Primary outcome
The difference in serum sodium change over 24 hours between patients receiving NS versus RL
Time frame: 24 hours
9 secondary outcomes
The difference in serum pH
Time frame: 24 hours
The difference serum chloride
Time frame: 24 hours
The differences in serum bicarbonate
Time frame: 24 hours
The differences in serum inflammatory biomarker change: Erythrocyte Sedimentation Rate (ESR)
Time frame: 24 hours
The differences in serum inflammatory biomarker change: C-Reactive Protein
Time frame: 24 hours
The differences in serum inflammatory biomarker change: InterLeukin-6
Time frame: 24 hours
The differences in serum inflammatory biomarker change InterLeukin-8
Time frame: 24 hours
The differences in serum inflammatory biomarker change: G-CSF
Time frame: 24 hours
The differences in serum inflammatory biomarker change: MCP-1
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2018.
Related trials for Trauma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
Safety Study of Microlyte DualGuard
Wound Closure, Wound Care
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gurinder S Sangha, MD principal investigator
London Health Sciences Centre, University of Western Ontario
Douglas D Fraser, MD, PhD principal investigator
London Health Sciences Centre, University of Western Ontario
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Normal Saline and Ringer's Lactate in people with Trauma, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in serum sodium change over 24 hours between patients receiving NS versus RL (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2018.